1025066-50-5

Basic information

• Product Name: 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid-8-aminocaprylic acid-Phe-Phe-2, 3-diaminopropianic acid-Asp-Cys
• Synonyms: 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid-8-aminocaprylic acid-Phe-Phe-2, 3-diaminopropianic acid-Asp-Cys
• CAS NO: 1025066-50-5
• Molecular Weight: 1060.15
• Mol File: 1025066-50-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid-8-aminocaprylic acid-Phe-Phe-2, 3-diaminopropianic acid-Asp-Cys(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid-8-aminocaprylic acid-Phe-Phe-2, 3-diaminopropianic acid-Asp-Cys(1025066-50-5)
• EPA Substance Registry System: 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid-8-aminocaprylic acid-Phe-Phe-2, 3-diaminopropianic acid-Asp-Cys(1025066-50-5)

Safety Data

• Hazardous Substances Data: 1025066-50-5(Hazardous Substances Data)

Upstream product

• 1026987-94-9 (S)-5-(tert-butoxy)-4-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)ureido)-5-oxopentanoic acid 
• 35661-40-6 N-Fmoc L-Phe 
• 71989-14-5 Fmoc-(tBu)Asp-OH 
• 126631-93-4 8-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)octanoic acid 
• 201473-90-7 N^α,N^β-di[(9-fluorenylmethyl)oxycarbonyl]-(S)-2,3-diaminopropionic acid 
• 131570-56-4 Boc-Dap(Fmoc)-OH 
• 181954-34-7 3-amino-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanine 

Downstream Products

• 1333158-82-9 C₉₀H₁₁₉N₁₃O₃₀S₄ 

Relevant articles and documents

DUPA Conjugation of a Cytotoxic Indenoisoquinoline Topoisomerase i Inhibitor for Selective Prostate Cancer Cell Targeting

(Figure Presented). Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate cancer cells while being present at low or undetectable levels in normal cells. This difference provides an opportunity to selectively deliver cytotoxic drugs

METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND

The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a PSMA ligand-tubulysin compound. The invention described herein also relates to methods of treating PSMA-expressing cancers with a PSMA ligand-tubulysin compound in patients where stable disease results after treatment with the PSMA ligand-tubulysin compound.

Ex vivo flow cytometry method and device

The invention relates to a method for diagnosing a disease state mediated by pathogenic cells. The method comprises the steps of combining with an ex vivo patient sample a composition comprising a conjugate or complex of the general formula [in-line-formulae]Ab-X[/in-line-formulae] wherein the group Ab comprises a ligand that binds to the pathogenic cells and the group X comprises an imaging agent, and detecting the pathogenic cells that express a receptor for the ligand using flow cytometry.